Literature DB >> 30676805

Criminal Justice Barriers to Treatment of Opioid Use Disorders in the United States: The Need for Public Health Advocacy.

Joanne Csete1.   

Abstract

Expanding access to treatment of opioid use disorder (OUD) is central to addressing the US overdose mortality crisis. Numerous barriers to OUD treatment are encountered in criminal justice institutions and processes, with which people with OUD are disproportionately involved. OUD treatment access is severely limited in US corrections facilities, with few exceptions. Drug treatment courts, which in principle provide court-supervised treatment as an alternative to prison, have also unduly limited treatment options, particularly medication-assisted treatment. The voice and expertise of health professionals are urgently needed to remove these barriers and ensure that criminally accused persons are systematically linked to the care they need.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30676805      PMCID: PMC6366485          DOI: 10.2105/AJPH.2018.304852

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  7 in total

1.  Release from prison--a high risk of death for former inmates.

Authors:  Ingrid A Binswanger; Marc F Stern; Richard A Deyo; Patrick J Heagerty; Allen Cheadle; Joann G Elmore; Thomas D Koepsell
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

2.  Seattle's Law Enforcement Assisted Diversion (LEAD): Program effects on recidivism outcomes.

Authors:  Susan E Collins; Heather S Lonczak; Seema L Clifasefi
Journal:  Eval Program Plann       Date:  2017-05-10

3.  Medication assisted treatment in US drug courts: results from a nationwide survey of availability, barriers and attitudes.

Authors:  Harlan Matusow; Samuel L Dickman; Josiah D Rich; Chunki Fong; Dora M Dumont; Carolyn Hardin; Douglas Marlowe; Andrew Rosenblum
Journal:  J Subst Abuse Treat       Date:  2012-12-03

4.  Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.

Authors:  Joshua D Lee; Edward V Nunes; Patricia Novo; Ken Bachrach; Genie L Bailey; Snehal Bhatt; Sarah Farkas; Marc Fishman; Phoebe Gauthier; Candace C Hodgkins; Jacquie King; Robert Lindblad; David Liu; Abigail G Matthews; Jeanine May; K Michelle Peavy; Stephen Ross; Dagmar Salazar; Paul Schkolnik; Dikla Shmueli-Blumberg; Don Stablein; Geetha Subramaniam; John Rotrosen
Journal:  Lancet       Date:  2017-11-14       Impact factor: 79.321

5.  Postincarceration Fatal Overdoses After Implementing Medications for Addiction Treatment in a Statewide Correctional System.

Authors:  Traci C Green; Jennifer Clarke; Lauren Brinkley-Rubinstein; Brandon D L Marshall; Nicole Alexander-Scott; Rebecca Boss; Josiah D Rich
Journal:  JAMA Psychiatry       Date:  2018-04-01       Impact factor: 25.911

6.  Methadone treatment providers' views of drug court policy and practice: a case study of New York State.

Authors:  Joanne Csete; Holly Catania
Journal:  Harm Reduct J       Date:  2013-12-05

7.  Health, Polysubstance Use, and Criminal Justice Involvement Among Adults With Varying Levels of Opioid Use.

Authors:  Tyler N A Winkelman; Virginia W Chang; Ingrid A Binswanger
Journal:  JAMA Netw Open       Date:  2018-07-06
  7 in total
  8 in total

Review 1.  First Responder Assertive Linkage Programs: A Scoping Review of Interventions to Improve Linkage to Care for People Who Use Drugs.

Authors:  Nancy Worthington; Talayha Gilliam; Sasha Mital; Sharon Caslin
Journal:  J Public Health Manag Pract       Date:  2022 Nov-Dec 01

2.  A national survey of barriers and facilitators to medications for opioid use disorder among legal-involved veterans in the Veterans Health Administration.

Authors:  Emmeline N Taylor; Christine Timko; Ingrid A Binswanger; Alex H S Harris; Matthew Stimmel; David Smelson; Andrea K Finlay
Journal:  Subst Abus       Date:  2021-09-29       Impact factor: 3.984

3.  Medications for opioid use disorder among pregnant women referred by criminal justice agencies before and after Medicaid expansion: A retrospective study of admissions to treatment centers in the United States.

Authors:  Tyler N A Winkelman; Becky R Ford; Rebecca J Shlafer; Anna McWilliams; Lindsay K Admon; Stephen W Patrick
Journal:  PLoS Med       Date:  2020-05-18       Impact factor: 11.069

4.  Opioid agonist treatment scale-up and the initiation of injection drug use: A dynamic modeling analysis.

Authors:  Charles Marks; Annick Borquez; Sonia Jain; Xiaoying Sun; Steffanie A Strathdee; Richard S Garfein; M-J Milloy; Kora DeBeck; Javier A Cepeda; Dan Werb; Natasha K Martin
Journal:  PLoS Med       Date:  2019-11-26       Impact factor: 11.069

5.  Opioid agonist treatment (OAT) experiences and release plans among federally incarcerated individuals with opioid use disorder (OUD) in Ontario, Canada: a mixed-methods study.

Authors:  Cayley Russell; Frishta Nafeh; Michelle Pang; Shanna Farrell MacDonald; Dena Derkzen; Jürgen Rehm; Benedikt Fischer
Journal:  BMC Public Health       Date:  2022-03-04       Impact factor: 3.295

6.  "I got a bunch of weed to help me through the withdrawals": Naturalistic cannabis use reported in online opioid and opioid recovery community discussion forums.

Authors:  Meredith C Meacham; Alicia L Nobles; D Andrew Tompkins; Johannes Thrul
Journal:  PLoS One       Date:  2022-02-08       Impact factor: 3.240

7.  Use of Project ECHO to promote evidence based care for justice involved adults with opioid use disorder.

Authors:  Zachary W Adams; Jon Agley; Casey A Pederson; Lauren A Bell; Matthew C Aalsma; TiAura Jackson; Miyah T Grant; Carol A Ott; Leslie A Hulvershorn
Journal:  Subst Abus       Date:  2021-07-20       Impact factor: 3.716

8.  Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review.

Authors:  Monica Malta; Thepikaa Varatharajan; Cayley Russell; Michelle Pang; Sarah Bonato; Benedikt Fischer
Journal:  PLoS Med       Date:  2019-12-31       Impact factor: 11.069

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.